Mantle Cell Lymphoma: ASH Highlights & Key Findings

ORLANDO — In this video, Ann S. LaCasce, MD, MMSc, discusses highlights in mantle cell lymphoma presented at ASH Annual Meeting and Exposition.

Highlights included data on triplet therapies, which included Bruton tyrosine kinase inhibitors, BCL2 inhibitors and CD20 antibodies.

“All of these looked really good,” LaCasce, associate professor of medicine at Harvard Medical School and director of the Dana-Farber/Mass General Brigham fellowship in hematology/oncology, said. “I do think we’re going to need longer-term follow-up and randomized trials to really assess the long-term benefit.”

Published by:

Sources/Disclosures

Source:

Healio Interviews

References:

• Kim A, et al. Abstract 4408. Presented at: ASH Annual Meeting and Exposition; Dec. 6-9, 2025; Orlando.
• Kumar A, et al. Abstract 888. Presented at: ASH Annual Meeting and Exposition; Dec. 6-9, 2025; Orlando.

.

Disclosures:
LaCasce reports no relevant financial disclosures.

Ask a clinical question and tap into Healio AI’s knowledge base.

• PubMed, enrolling/recruiting trials, guidelines
• Clinical Guidance, Healio CME, FDA news
• Healio’s exclusive daily news coverage of clinical data

Learn more

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

“
data-action=”subscribe”>
Subscribe

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio